Biomerica Reports Fiscal 2025 Year End Results

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio
Biomerica's inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods® IBS Test in the U.S.
Biomerica Reports First Quarter Fiscal 2026 Financial Results
Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes
United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® Kidney Test for Home Use

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.